Each of three isolates from the former group had mutations in parC, whereas each of nine isolates from the more resistant group had mutations in both parC and gyrA. Several also had increased quinolone efflux. Typing of 27 quinolone-resistant isolates showed that eight were indistinguishable from the epidemic Spain 9V -3 (ST156) clone, while the remainder belonged to a novel but related type (ST609), that differed from Spain 9V -3 at 2/7 alleles (2 bp changes in aroE and 1 bp change in gdh). Both MLST types were represented among isolates with high-and low-level quinolone resistance. Three of five serotype 9V isolates from Birmingham, with reduced susceptibility to penicillin and erythromycin, and ciprofloxacin MICs of 1-2 mg/L, belonged to MLST type ST609, while another was indistinguishable from the Spain 9V -3 clone. Review of records of 32 patients from Birmingham indicated that some isolates were nosocomial, whereas others were acquired in the community.
Introduction
Pneumococci resistant to β-lactams, macrolides and tetracyclines are increasingly prevalent in many parts of the world. 1, 2 Their epidemiology is complex, involving de novo emergence of resistance via mutation or acquisition of foreign DNA, as well as the spread of resistant strains. Typing by PFGE and multilocus sequence typing (MLST) has shown much resistance is clonal, with multiresistant clones of serotypes 6B, 9V and 23F having spread within and between countries and continents. [3] [4] [5] The treatment of multiresistant pneumococcal infections is problematic, and there is a need for new agents, particularly those suitable for oral administration. Several fluoroquinolones with enhanced anti-pneumococcal activity and favourable pharmacokinetics were developed during the 1990s, 6 and are now included among the agents recommended by several expert panels for patients with pneumonia, particularly where penicillin-or macrolide-resistant Streptococcus pneumoniae is known or suspected. [7] [8] [9] [10] Surveys show that quinolone resistance in pneumococci is rare in many countries, although data from Canada indicate the beginnings of a rising trend. 11 Exceptionally, the prevalence of resistance to fluoroquinolones is already high in pneumococci from Hong Kong. 12 In an earlier investigation, we evaluated moxifloxacin against a collection of referred pneumococci with elevated resistance to ciprofloxacin. 13 In assembling the panel of isolates, it was noted that half were phenotypically similar, belonging to serotype 9V and showing reduced susceptibility to penicillin and erythromycin. Most of these isolates had been referred, over several years, from Birmingham Public Health Laboratory (PHL) (now Birmingham Health Protection Agency Laboratory). This raised the possibility that a quinoloneresistant strain might have become established in Birmingham. We present here a detailed molecular study to determine the clonal relationship of these and other isolates with the same resistance phenotype, referred from Birmingham and elsewhere in the UK.
Materials and methods

Bacterial isolates
Isolates for study were selected by searching the databases of the Central Public Health Laboratory, to identify pneumococci referred during 1997-2001 that had the same phenotype as the isolates studied previously, namely serotype 9V, penicillin MICs ≥ 1 mg/L, erythromycin MICs ≥ 2 mg/L and ciprofloxacin MICs ≥ 8 mg/L (the highest concentration routinely tested). A further five isolates referred from Birmingham PHL in 1997, which were phenotypically similar, except for having ciprofloxacin MICs of 1-2 mg/L, were also included. All the isolates were recovered from frozen stocks, and had their serotype and antibiogram reconfirmed. The Pneumococcal Molecular Epidemiology Network reference strain for the Spain 9V -3 clone, S. pneumoniae ATCC 700671, served as a reference for MLST and PFGE typing. 5 
Patient data
Clinical details of the patients whose isolates were referred from Birmingham PHL were reviewed retrospectively from case notes, hospital infection control records and the hospital admissions database. Antibiotic prescribing data for the Thoracic Medicine Department of Birmingham Heartlands Hospital during April 1996-April 2001 were obtained from pharmacy records. The Local Ethics Committee Chairman advised that this review of patients' records did not require formal Ethics Committee approval.
Susceptibility tests
MICs were determined in air on Diagnostic Sensitivity Test agar (Oxoid, Basingstoke, UK) containing 5% lysed horse blood (TCS Microbiology, Buckingham, UK), as described previously. 13 Isolates were categorized as susceptible or resistant using breakpoints recommended by the British Society for Antimicrobial Chemotherapy. 14 
Serotyping
Serotypes of pneumococci were determined by slide agglutination with capsular typing sera. 15, 16 Multilocus sequence typing MLST was performed as described previously. 17 In brief, internal fragments of the genes aroE, gdh, gki, recP, spi, xpt and ddl were amplified by PCR, and the sequences of each amplicon were determined in both the forward and reverse directions, using the Dye Terminator Cycle Sequencing Quick Start Kit (Beckman-Coulter, Fullerton, CA, USA) and analysed on a CEQ 2000 DNA Analysis System (Beckman-Coulter). The sequences were then compared with those of all the recognized alleles of each gene listed in the pneumococcal MLST website database (http://spneumoniae.mlst.net). Sequences that were identical to those of a known allele were assigned the same allele number, whereas novel sequences were submitted, with the original CEQ sequence trace files, to the database curator, who assigned new allele numbers. The resulting allelic number profiles were checked against the database to find the corresponding sequence type (ST) numbers. Allelic profiles not represented were submitted to the database curator for assignment of new ST numbers. The MLST allele profile data were analysed using BioNumerics software (Applied Maths, Kortrijk, Belgium) with a categorical data analysis method. Trees were drawn using the unweighted pair group method with arithmetic means (UPGMA).
Pulsed-field gel electrophoresis
Low-melting-point agarose gel blocks containing bacteria were prepared, and the cells were lysed following the protocol of McEllistrem et al., 18 with modifications. Specifically, the DNA was digested with 20 U of SmaI overnight at 30°C and electrophoresed on a 1% agarose gel in a CHEF DR II PFGE tank, with an initial switch time of 0.5 s, rising to 25 s over 28 h. Photographs of the gels were analysed using BioNumerics software, and clustering of PFGE patterns was performed by Pearson correlation, allowing a UPGMA tree to be drawn.
Sequencing of the quinolone resistance determining regions of gyrA and parC
Mutations in the quinolone resistance determining regions of gyrA and parC were investigated for 12 isolates. PCR amplifications were performed as previously described, 19 using the primer pairs VGA3 and VGA4 for parC, and M0363 and M4271 for gyrA, and amplicons were sequenced as above. Sequences were analysed using BioNumerics and Genebase software (Applied Maths), and compared with reference sequences for a quinolone-susceptible isolate (gyrA, GenBank accession no. AJ005815; parC, GenBank accession no. Z67739).
Determination of efflux phenotype
To ascertain if efflux played a role in reduced susceptibility to quinolones, MICs of norfloxacin and ethidium bromide were determined in the presence and absence of the efflux pump inhibitor reserpine (10 mg/L). 20 Efflux-mediated resistance was inferred from resistance to norfloxacin (MIC > 8 mg/L) and ethidium bromide (MIC > 16 mg/L), together with a four-fold or greater reduction in the MIC of norfloxacin in the presence of reserpine. The efflux phenotype was confirmed by transforming the ethidium bromide resistance into S. pneumoniae strains R6 and R6(pmrA::cat), as previously described. 21, 22 Transformants were selected on Columbia blood agar containing ethidium bromide at 4 mg/L, and resistance was confirmed by subculture onto fresh medium containing ethidium bromide at 6 mg/L.
Results
Study isolates
Interrogation of the reference laboratory databases revealed that 48 isolates received during 1997-2000 met the inclusion criteria, being of serotype 9V, with ciprofloxacin MICs ≥ 8 mg/L and penicillin MICs ≥ 1 mg/L. All except one also had low-level resistance to erythromycin (MICs 2-8 mg/L). Thirty-five of the isolates were received from Birmingham PHL. Of these, 32 were from respiratory samples (30 sputa and two bronchial traps) and three were from blood cultures. The other 13 isolates were from eight other hospitals. One hospital was located in Sutton Coldfield, ∼7 miles north of Birmingham, five were in areas (Stoke-on-Trent, Shrewsbury, Chester, Merseyside, and the Wirral) 50-95 miles to the north or north-west of Birmingham, and the other two were in London and Portsmouth, both over 100 miles away.
When MICs of quinolones were re-determined using an extended range of concentrations, two quinolone resistance phenotypes were observed among the isolates. Eighteen isolates, designated as having low-level quinolone resistance (LLQR) were resistant to ciprofloxacin (MICs 8-32 mg/L), and had moxifloxacin and gemifloxacin MICs that were either on or two-fold below their breakpoints (MICs 0.5-1 and 0.125-0.25 mg/L, respectively). The remaining 30 isolates were designated as having high-level quinolone resistance (HLQR), with ciprofloxacin, moxifloxacin and gemifloxacin MICs of 64-256, 4-16 and 1-4 mg/L, respectively. Nine of the 35 isolates from Birmingham PHL and 8/13 isolates from elsewhere, had the LLQR phenotype, whereas 26/35 Birmingham isolates and 5/13 isolates from elsewhere had the HLQR phenotype.
Patient details
The 35 isolates from Birmingham PHL were from 33 patients (20 males, 13 females), all aged ≥50 years (four were aged 50-59 years, six were 60-69 years, 17 were 70-79 years and six were >80 years old).
Clinical records were available for 32 of these patients (31 inpatients and one outpatient), and showed that most had acute respiratory tract infections (17 were diagnosed with pneumonia and seven with exacerbations of airway disease) and/or underlying chronic obstructive pulmonary disease (n = 26). Recurrent admissions to the hospital were common, with 16 source patients (50%) having had an admission in the preceding 3 months. Sixteen inpatients had isolates collected more than 1 week after admission, and 12 had a preceding negative sputum culture, implying nosocomial infection. Potential epidemiological links were observed for some patients, suggesting nosocomial spread of the resistant pneumococci. A cluster of five cases occurred in succession during late November 1997-early January 1998 on one ward, together with two on another ward ( Table 1) . Six of these seven isolates were collected on or after the third day of admission (range 3-40 days), the exception being one that was collected on the day of admission. The source patient for this latter isolate had recently been discharged from the other affected ward. MLST (see below) showed that the isolates from six of these seven patients belonged to ST609 (the other isolate belonged to ST156), which is consistent with interpatient spread of infection.
Another cluster in Birmingham occurred during January-March 1999, and involved 13 patients (Table 1) . Three patients had isolates collected on admission; one had been discharged only a few days previously from the same ward, whilst two had no previous admissions documented within the last 6 months. Infection control data recorded contact between two cases on a surgical ward (Ward C, between three cases on a general medical ward (Ward B). The primary case had been in close contact with a subsequent case, who, in turn, was a contact of the third case. Thus, there appeared to be a mixture of both hospital and community transmission. In 2000, four patients also appeared to have community-acquired infections; three were inpatients who yielded positive cultures within one day of admission and had not been hospitalized in the preceding 3 months, and the other was an outpatient. Twenty-seven of the patients whose isolates were referred from Birmingham PHL were under the care of physicians at one Birmingham hospital. In 1997, the hospital's antibiotic policy for the first-line treatment of pneumonia was changed from amoxicillin and erythromycin to ofloxacin, with or without penicillin. Figure 1 shows the Respiratory Directorate's increased use of ofloxacin, and to a lesser extent, ciprofloxacin and penicillin V, during this period, with a concurrent reduction in amoxicillin use. Review of the records of 32 patients showed that quinolones had been prescribed in 20 (63%), penicillin in 12 (38%) and amoxicillin in three (9%), during the 3 months before isolation. Of the 20 patients prescribed a quinolone, 18 received ofloxacin and two received ciprofloxacin. Unfortunately, clinical records were not available for the patients from the other hospitals.
Multilocus sequence typing
Thirty-two serotype 9V isolates were examined by MLST. These were selected so as to include quinolone-susceptible (n = 5), LLQR (n =7) and HLQR (n = 7) phenotypes from Birmingham, and all 13 resistant isolates from the other referring hospitals (Table 2) .
Among the five quinolone-susceptible isolates, all referred from Birmingham in 1997, one belonged to ST156, the same ST as the international clone Spain 9V -3, while one other exhibited a novel but closely related ST, designated ST608, that differed from ST156 at the xpt allele (four base pair differences). The other three isolates belonged to another novel ST, designated ST609, which differed from ST156 at two alleles, with two base pair differences in aroE and one base pair difference in gdh. Among 14 LLQR or HLQR isolates examined from Birmingham PHL, one belonged to ST156, while the other 13 belonged to ST609 (Table 2 ). Among the 13 isolates from other laboratories, each of four LLQR isolates from a hospital in Merseyside, and two HLQR isolates, one from Sutton Coldfield and one from Shrewsbury, belonged to ST609. The other seven isolates (four LLQR and three HLQR), referred from five hospitals, all belonged to ST156 ( Table 2) .
Pulsed-field gel electrophoresis
DNA from 12 representative isolates and S. pneumoniae ATCC 700671 (the reference strain of the Spain 9V -3 clone) was subjected to PFGE analysis. The 12 isolates were selected to include representatives from Birmingham PHL and four other centres, the three MLST types observed, quinolone-susceptible, LLQR and HLQR phenotypes, and isolates with different gyrA and parC mutations (see below). All the tested isolates showed possible or close relationships to the Spain 9V -3 reference strain ( Figure 2) ; three gave identical patterns over at least 13 fragments, while the remainder showed between two and four band differences from the reference isolate, and thus would be classified as 'closely' or 'possibly' related to Spain 9V -3, based on Tenover's criteria. 23 
Typing based on combined MLST and PFGE data
The PFGE and MLST data were combined, using BioNumerics software, to produce the relatedness dendrogram shown in Figure 3 . This analysis confirmed that the penicillin-and quinolone-resistant serotype 9V pneumococci from Birmingham and elsewhere in the UK are closely related to the Spain 9V -3 (ST156) clone, but clustered into two broad groups, corresponding to ST156 and its newly described twolocus variant, ST609, respectively. Isolates with LLQR and HLQR were indistinguishable by PFGE and MLST, suggesting sequential acquisition of quinolone resistance mutations within each of the related lineages.
Sequencing of the quinolone resistance determining regions of gyrA and parC
Amino acid substitutions, inferred from DNA sequence changes for three isolates with LLQR and nine isolates with HLQR, are shown in Table 3 . Among the LLQR isolates (all ST609), there were no changes to GyrA, but all three showed changes at amino acids 79 and 137 in ParC. In two LLQR isolates from Birmingham PHL, the change at position 79 was Ser→Tyr, whereas in an LLQR isolate from Merseyside, the change was Ser→Phe. In all three isolates, the change at position 137 was Lys→Asn. Each of nine isolates of the HLQR phenotype had mutations in both parC and gyrA. In eight of these, GyrA had the amino acid substitution Ser-83→Phe, with Ser-83→Val in the other one. In seven of the nine, the mutations in parC caused the amino acid substitution Ser-79→Tyr, whereas the change Ser-79→Phe was seen in the other two. All nine isolates had other mutations in parC causing the change Lys-137→Asn (Table 3) .
Efflux phenotype
Thirteen of the 48 isolates, including representatives from Birmingham and six other centres, showed an efflux phenotype. Efflux was variably present in isolates of the LLQR (8/18) and HLQR (5/30) phenotypes, and was also variably present in isolates of ST609 and ST156. The efflux phenotype from a selection of nine isolates was transformed successfully into both R6 and R6(pmrA::cat).
Discussion
Quinolone resistance is slowly emerging in pneumococci, although the epidemiology seems to vary with the place. In Spain, there is considerable genetic diversity among resistant isolates, suggesting that resistance had emerged repeatedly through independent mutational events. 24 In contrast, a dramatic increase in the prevalence of quinolone-resistant pneumococci in Hong Kong reflected the dissemination of a multiresistant clone. 25 Our typing data also indicate clonal spread, specifically of closely related quinolone-resistant lineages of serotype 9V. MLST analysis indicated that a clone of quinolone-resistant S. pneumoniae, designated ST609, emerged and persisted in the patient catchment area for Birmingham PHL for several years. This conclusion was reinforced by PFGE analysis, which confirmed that representative isolates were highly related. The quinolone-resistant clone was not, however, confined to the patient catchment area of Birmingham PHL, as isolates of the same ST were also received from three other hospitals. One was in Sutton Coldfield, which is only about 7 miles north of Birmingham PHL, whereas the other two were Nosocomial spread of quinolone-resistant pneumococci has been documented previously in the USA. 27 There was also strong evidence of nosocomial infection in this study, although the high re-admission rates of some of the Birmingham patients makes it difficult to determine where acquisition occurred. On the other hand, there was also evidence of community spread, with resistant isolates obtained within 1 day of admission from three inpatients-none of whom had been hospitalized in the preceding 3 months-as well as from one outpatient.
Quinolone-susceptible isolates of ST609 were present in Birmingham in 1997, and possibly before then. The earliest variants with the LLQR phenotype also date from 1997, and those with the HLQR phenotype from 1998. The latter organisms appear to have emerged as a result of sequential mutations in parC and gyrA. The association of changes in parC in pneumococci with low-level quinolone resistance, and additional changes in gyrA in isolates with a higher level of quinolone resistance, are consistent with previous reports, several of which describe the same mutations as found here. 28, 29 Whilst efflux only has a small effect on ciprofloxacin MICs it may help cells resist low levels of antibiotic, and thereby allow the accumulation of further resistance mutations. 20, 21 However, the function of such pumps requires cellular energy, and once a cell has developed high-level resistance due to topoisomerase mutations, there is no need for the expenditure of this energy and the selective advantage of maintaining the efflux pump may be lost. It is not surprising to find the efflux phenotype to be less frequent in pneumococci with HLQR. We were able to transform the efflux phenotype into a pneumococcus in which pmrA was insertionally inactivated. This is evidence that systems other than PmrA may be contributing to efflux. Such PmrA-independent efflux has been described previously in laboratory mutants 21 and is not surprising since genome sequencing of pneumococci indicates a large number of putative multi-facilitator and ABC superfamily efflux pump genes.
Modelling studies suggest that the risk of an individual being colonized by pneumococci is independent of antibiotic exposure. 30 When, however, individuals are colonized by pneumococci, the risk of these being antibiotic-resistant is related to antibiotic exposure. A multivariate case-control analysis previously identified chronic obstructive pulmonary disease and quinolone exposure as risk factors for acquisition of fluoroquinolone-resistant strains. 31 Review of the clinical records for Birmingham patients from whom quinolone-resistant pneumococci of ST609 were obtained revealed that most had been prescribed ofloxacin or ciprofloxacin for lower respiratory tract infections. Although this use of quinolones is supported by some authorities and guidelines, 7-10 these mostly recommend the use of newer quinolones such as moxifloxacin, which have enhanced anti-pneumococcal activity and a lower potential to select first-and second-step quinolone-resistant mutants. It is possible that the documented use of ofloxacin or ciprofloxacin, which have poorer anti-pneumococcal activity, provided the selective pressure for the emergence and persistence of the quinolone-resistant strains described here. However, we cannot discount the possibility that the use of penicillin or erythromycin, to which the isolates were also resistant, may have exerted an additional selective pressure, either in the hospital or community. Spread of quinolone-resistant variants of the ST609 clone does not yet seem to have impacted significantly on the overall prevalence of quinolone resistance of S. pneumoniae in the UK, 32 but the presence of this clone, related to the highly successful pandemic pneumococcal strain Spain 9V -3, is a cause for concern. Continued surveillance, coupled with molecular characterization of isolates is clearly warranted to monitor further dissemination.
